My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

NovoCure Limited - Ordinary Shares (NQ:NVCR)

14.35 -0.52 (-3.50%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

19 20 Next >

Why Novocure Stock Was so Healthy Today ↗

February 15, 2023

There was good news from the laboratory on Hump Day.

Via The Motley Fool

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

February 15, 2023

From Novocure

Via Business Wire

Why Novocure Stock Is Sliding Today ↗

January 19, 2023

Investors reacted negatively to the oncology treatment specialist's game of C-suite musical chairs.

Via The Motley Fool

Novocure Round-Trips Its Recent Breakout After Announcing A Series Of C-Suite Changes ↗

January 19, 2023

A series of unexpected C-suite changes sent shares diving again.

Via Investor's Business Daily

Novocure Announces Organizational Changes to Prepare for Future Growth

January 19, 2023

From Novocure

Via Business Wire

Will Novocure Stock Sink or Soar in 2023? ↗

January 19, 2023

The stock has both soared and sank already this year.

Via The Motley Fool

Why Novocure Stock Is Sinking Today ↗

January 09, 2023

The company provided a disappointing sneak peek at its Q4 results.

Via The Motley Fool

Why Novocure Stock Is Flying High ↗

January 06, 2023

Here's why Novocure stock popped over 68% on Jan. 5.

Via The Motley Fool

Novocure Has Fallen More Than 20% Over Seven Days — Why It Fell From Grace ↗

January 17, 2023

Shares have given back a chunk of their 69% single-day gain on a lung cancer study.

Via Investor's Business Daily

Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update

January 09, 2023

From Novocure

Via Business Wire

Is NovoCure a Good Stock to Buy Right Now? ↗

January 07, 2023

Successful clinical trial results recently pushed this stock more than 68% higher overnight -- but what about the road ahead?

Via The Motley Fool

Stock Market Mostly Higher Amid Jobs Report; Tesla Price Cuts, GE Spinoff In Focus: Weekly Review ↗

January 06, 2023

The major indexes rallied Friday on the jobs report and services data.

Via Investor's Business Daily

Why Novocure Stock Is Skyrocketing Today ↗

January 05, 2023

The company announced good news from a late-stage study of its Tumor Treating Fields therapy.

Via The Motley Fool

Novocure Skyrockets After Pulling Off A Once-In-Six-Years Feat ↗

January 05, 2023

The company is now planning to ask for FDA approval in the second half of 2023.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023 ↗

January 06, 2023

Via Benzinga

Tesla, Amazon, Aehr, Silvergate, Novocure: Why These 5 Stocks Are Drawing Investors' Attention Today ↗

January 05, 2023

Major Wall Street indices closed over 1% lower on Thursday, dragged by strong employment data which could nudge the Federal Reserve to continue its rate hikes.

Via Benzinga

Why Shares of Zai Lab Soared This Week ↗

January 05, 2023

A strong phase-3 clinical trial boosted investors' hopes for the Chinese biotech company.

Via The Motley Fool

Dow Falls Over 200 Points; Walgreens Earnings Top Expectations ↗

January 05, 2023

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 200 points on Thursday.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

January 05, 2023

Via Benzinga

Nasdaq Down Over 100 Points; Crude Oil Rises 1% ↗

January 05, 2023

U.S. stocks traded lower midway through trading, with the Nasdaq Composite shedding more than 100 points on Thursday.

Via Benzinga

Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

January 05, 2023

Gainers Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares surged 179.3% to $2.4585 after the company announced that it has entered into a license agreement for the development and commercialization...

Via Benzinga

Why Is Huadi International (HUDI) Stock Up 30% Today? ↗

January 05, 2023

Huadi International (HUDI) stock is climbing higher on Thursday even without specific news from the Chinese steel company.

Via InvestorPlace

Why Is Magic Empire Global (MEGL) Stock Up 83% Today? ↗

January 05, 2023

Magic Empire Global (MEGL) stock is rocketing higher on Thursday despite a lack of news from the Hong Kong financial services provider.

Via InvestorPlace

NovoCure (NVCR) Stock Soars 50% on Positive Clinical Trial Results ↗

January 05, 2023

NVCR stock traders are undeniably pleased to see NovoCure marking a milestone in the company's quest to treat a specific type of lung cancer.

Via InvestorPlace

Novocure Stock Surges As Tumor Treating Fields Shows Overall Survival In Lung Cancer Patients ↗

January 05, 2023

Via Benzinga

This Good News on Cancer Sent 2 Nasdaq Stocks Soaring ↗

January 05, 2023

Biotech investors are optimistic about the prospects for a potential treatment.

Via The Motley Fool

US Stocks Open Lower; Dow Tumbles 300 Points ↗

January 05, 2023

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 300 points on Thursday.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

January 05, 2023

Via Benzinga

Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

January 05, 2023

From Zai Lab Limited

Via GlobeNewswire

Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

January 05, 2023

From Novocure

Via Business Wire

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.